Tikva has an exclusive partnership with Panaxia Pharmaceutical Industries – a world - renowned Israeli Pharmaceutical company with over a decade of clinical research in medical cannabis. Thanks to their relentless emphasis on research and development, their entire gr oup of companies, founded over 40 years ago, offers more than 600 medical products in over 30 international markets to treat a wide range of symptoms and conditions

Why does Tikva partner with an Israeli company to manufacture our products? It was an Isr aeli scientist, Dr. Raphael Mechoulam, who first discovered THC, CBD, and the entire endocannabinoid system in the 1960s. Israel continues to lead the world in medical cannabis research and product development.

In 2009, Panaxia was the first company granted a license by the Israeli Ministry of Health to conduct clinical research and make pharmaceutical cannabis products under stringent Good Manufacturing Practices (GMP) guidelines. This certification ensures and mandates that Panaxia products are manufactured to the most demanding requirements for validation and standardization.

Tikva products are manufactured by Panaxia and are subjected to stringent quality assurance protocols and the predetermined specifications required of pharmaceutical medicines. While most CBD companies perform the minimum requirement of third - party tests o n their final product, Panaxia conducts three internal tests through the manufacturing process to guarantee safety and consistency.

For more than a decade, Panaxia has conducted numerous clinical trials on medicinal cannabis, including studies on migraines, kidney disease, psoriasis, and epilepsy. Until recently, U.S. federal restrictions prohibited cannabis and hemp companies from conducting this type of research. As a result, Panaxia is a decade ahead with its product commercialization, clinical studies, and data collection.

To meet the pharmaceutical standard and quality requirements in the final product, the raw materials used at the beginning of the process must be considered. This means that Tikva requires rigorous testing to ensure the biomass meets predetermined specificatio ns before any other steps are taken.

Not only do we conduct more testing than our competitors, but our specifications are also significantly more stringent to comply with pharmaceutical standards. For example, the USDA requires the total aerobic micro - colony forming units to be less than 100,000, whereas the Tikva requirement is to be less than 10,000 colony-forming units. State mandatory testing requires one cannabinoid potency test to verify that the product doesn’t exceed the federally allowable amount of THC. We perform multiple cannabino id potency tests to gather statistically significant data for analysis of possible contaminants and to ensure product safety.

The main purpose of GMP is for ensuring that products are safe and consistently produced and controlled to qual ity standards.

Additional tenets include manufactu ring consistency, ensuring the end product is free from contamination, well-documented manufacturing, well-trained personnel, and quality checks throughout the manufacturing process—not just at the end p hase. At Tikva, we take GMP so seriously that e ven the primary and secondary packaging on all Tikva products are completed according to GMP requirements.

Once we have tested the U.S.-grown hemp biomass to ensure it meets our predetermined quality specifications, CBD is extracted in a GMP cleanroom environment using non-volatile ethanol extraction. This safe extraction method separates the CBD-rich oil and other beneficial minor cannabinoi ds and terpenes without leaving harmful chemical residue.

Pre-mixed excipients formulated to enhance stability, bioavailability, and delivery are sent from Panaxia’s GMP central production facilities in Israel or Malta directly to Panaxia’s site in the U.S. where they are mixed with our full-spectrum CBD extract. Panaxia then manufactures all Tikva products using their patented and proprietary processes and formulations.

Panaxia’s analytical methods go above and beyond what is required at a federal or state level in the U.S. Panaxia utilizes state - of - the - art technologies and facilities, and employs analytical methods and guidelines that are certified and meticulously referenced.

HPLC/UV–

Panaxia’s current analytical method uses HPLC/UV to identify and quantify: THC, THCA, CBD, CBDA, CBN, CBG, CBGA, CBC, and THCV. Their improved HPLC/UV analytical method reduces runtime while lowering costs. It also features an internal standard t o improve the monitoring of instrument performance.

LC/MS/MS–

Panaxia’s latest LC/MS/MS systems can quantify cannabinoids in blood samples, enabling them to perform Pharmacokinetic (PK) studies faster and more cost-effectively. The system can also ide ntify and quantify more cannabinoids, terpenes, and degradation products, enhancing the ability to develop innovative products that can treat a wide range of medical indications.

Tikva Product Testing

Only after passing multiple internal tests and ensu ring the product matches predetermined specifications are Tikva products sent to an ISO/IEC 17025 accredited laboratory for mandatory microbial and potency testing. Though third-party testing is required for all CBD products, using an ISO-accredited laboratory is not

All Tikva products are lot-track-traced with a batch and lot number on the bottom of the carton. To ensure safety and consistency, each product includes a batch-specific Certificate of Analysis and accompanying QR code on the carton.

Sometimes described as “what the body does to a drug,” Pharmacokinetics refers to the movement of a drug into, through, and out of the body – The time course of its absorption, bioavailability, distribution, metabolism, and excretion. Drug pharmacokinetics determines the onset, duration, and intensity of a drug's effect. (Le, 2022)

The administration method and formulation of a cannabis product are significant factors in determining the rate and extent of the absorption of the active ingredients into the bloodstream. Administration types greatly affect bioavailability by changing th e number of biologic barriers a drug must cross or by changing the exposure of a drug to pumping and metabolic mechanisms (Stan K. Bardal et. al, 2011.

Bioavailabi lity is the proportion of a drug or other substance that enters the blood circulation when introduced into the body and so is able to have an active effect. It is essential for a medical product to have high bioavailability to ensure the API (active pharma ceutical ingredient, in this case, CBD) achieves the desired goal and reaches the desired part of the body.

Unlike other cannabis companies, Panaxia supports Tikva’s products with pharmacokinetic data to know how fast and how completely the API is absorbed into the body.

Pharmaceutical formulation development is a crucial step to determine the optimal dosage, composition, and manufacturing process to achieve a product that is manufacturable, bioavailable, and chemically and physically stable through the manufacturing process and shelf life. Also, many quality standards and special requirements must be met to ensure the product’s efficacy and safety.

Panaxia currently holds seven patents on delivery methods and formulations.
Proprietary analytical me thods allow Panaxia’s R&D team to specify and standardize up to nine components in Tikva products. They also can identify and quantify eleven major and minor cannabinoids, including THC, THCA, CBD, CBDA, CBN, CBG, CBGA, CBC, THCV, delta - 8 - THC , and 11 - hydro xy - THC. Tikva products are always made from full - spectrum hemp extracts, not CBD isolates or broad - spectrum extracts.

Tikva formulations maximize absorption and bioavailability, which leads to consistently increased efficacy. The main raw plant materials and formulation excipients were selected to synergistically facilitate the functioning of the dominant plant actives (CBD).

For example, Tikva’s proprietary tablet formulations bypass the liver to avoid the first-pass effect, maximizing absorption for optimal therapeutic potential. Tikva’s CBD creams are formulated to penetrate the outer dermal layer of the skin, delivering CBD deep into the muscles to provide fast - acting, localized relief.

A cannabis product may say it has a high concentration of CBD, but it could have very low bioavailability, making it less effective than Tikva’s lower-concentration products with high bioavailability. Other products can lead to dosing uncertainty and overuse.

Tikva products are designed to be absorbed effectively, so we don’t need to hyper-concentrate our formulations. Highly bioavailable, lower-dosed products enable safe and effective dose titration, so your patients can feel confident while determining their optimal CBD dosage.

Instead of taking more and more milligrams of a CBD product that isn't being absorbed effectively into the body, your patients can take Tikva’s lower-dosed CBD specially made to maximize absorption to achieve maximum impact with less product.

Along with Pharmacokinetic studies, Panaxia performs stability testing on all Tikva products to ensure safety and verify shelf-life duration. Stability testing provides evidence on how the quality of a drug substance or drug product varies with time under the influence of environmental factors such as temperature, humidity, and light, and to establish a retest period and shelf-life. These tests are essential in traditional pharmaceuticals, and they should be applied to medical hemp and cannabis pro ducts as well.